Alphamab Oncology repurchases shares, increasing treasury holdings

Alphamab Oncology reported a repurchase of 293,000 ordinary shares on October 14, 2025, through the Exchange. These shares were repurchased at prices ranging from HK$13.03 to HK$13.83 per share, totaling an aggregate price paid of HK$3,966,900. The repurchase increased the company’s treasury shares from 3,060,000 to 3,353,000.

Following the repurchase, the number of issued shares (excluding treasury shares) decreased by 293,000 to 970,794,697, representing a 0.0302% change from the opening balance. The total number of issued shares remained at 974,147,697.

The company holds a repurchase mandate, granted on June 12, 2025, authorizing the repurchase of up to 96,218,980 shares. With the latest repurchase, Alphamab Oncology has now repurchased 401,000 shares under this mandate, which represents 0.0417% of the issued shares (excluding treasury shares) as of the mandate date. A moratorium period for new share issues or treasury share sales is in effect until November 13, 2025.